The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple ...
Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...
A newly discovered natural peptide called BRP shows promising weight loss effects without the side effects of Ozempic. Learn how this non-incretin hormone could revolutionize obesity treatment.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin ...
Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP ...
The identification of BRP, an anti-obesity peptide, showcases the transformative role of AI in drug discovery and its ...
BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...
News-Medical.Net on MSN17d
GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patientsBy Tarun Sai Lomte Could a diabetes drug slash your cancer risk? New research shows GLP-1 receptor agonists may protect patients with type 2 diabetes from deadly blood cancers—beyond just managing ...
A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide—also known as Ozempic—in suppressing appetite and reducing body weight. Notably, testing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback